1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
60AB531F149F281C500258ABE003AAF60
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-benchmarking-oncology-field-medical-excellence-apac-establishing-standards-high-performance-impact?opendocument
18
19opendocument
2044.210.149.205
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




» Products & Services » » Medical Affairs » Field Medical Excellence

Benchmarking Oncology Field Medical Excellence in APAC: Establishing Standards for High Performance & Impact

ID: 5793


Features:

9 Info Graphics

14 Data Graphics

110+ Metrics

7 Narratives


Pages/Slides: 28


Published: 2024


Delivery Format: Online PDF Document


 

License Options:


Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from “Benchmarking Oncology Field Medical Excellence in APAC: Establishing Standards for High Performance & Impact”

STUDY OVERVIEW

The Asia-Pacific (APAC) region stands at the forefront of oncology innovation, marked by swift advancements, diverse patient demographics, and evolving healthcare infrastructures. Within this dynamic landscape, maximizing the efficiency of field medical teams is imperative for manufacturers seeking to establish a stronghold.

Best Practices, LLC undertook this benchmarking research to guide Oncology field medical leaders in elevating performance and navigating the intricacies of the APAC market. By identifying effective performance metrics, developing optimal resourcing strategies, establishing frameworks for excellence, and analyzing engagement levels with KOLs, our study provides a roadmap for maximizing field medical impact in the APAC region.

KEY TOPICS

  • Effective Oncology Field Performance Metrics in the APAC Region
  • Building an Oncology Field Medical Excellence Framework
  • Target and Engagement Levels of Oncology KOLs in the APAC Region
  • Average Time Oncology MSLs Spend on KOL Interactions and Internal Activities in the APAC Region
  • Oncology Field Medical Staffing Footprint in the APAC Region
  • Key Insights and Lessons Learned for Measuring the Impact of Oncology MSLs in the APAC Region

KEY METRICS

  • APAC field scorecard: Benchmarking oncology engagements
  • Average total panel size supported by an individual Oncology MSL in the APAC region
  • Average number of monthly KOL/HCP and F2F meetings in the APAC region – Oncology segment
  • Value assigned to each interaction type on the Oncology MSL scorecard (APAC)
  • Engagement metrics for non-tiered Oncology KOLs in the APAC region
  • Average annual field presence of Oncology MSLs in the APAC region
  • Time spent by Oncology MSLs on external, internal, and logistics activities in the APAC region
  • Weekly Oncology MSL time allocation across activity streams in the APAC region
  • Oncology MSL engagement mix in the APAC region
  • Oncology field medical staffing footprint in the APAC region

SAMPLE KEY FINDINGS

  • Metrics for Engaging Non-Tiered Oncology KOLs in the APAC Region: One-third of oncology manufacturers from the APAC region employ special metrics for non-tiered Key Opinion Leaders (KOLs). Meanwhile, across all therapeutic areas, 40% of companies employ special metrics to assess the engagement of non-tiered KOLs.

METHODOLOGY

Best Practices, LLC collated performance data and insights from field medical executives from oncology companies around the world through a custom benchmark survey. Focused on oncology field medical operations, the research drew insights from a diverse range of respondents and was meticulously segmented at regional levels.


Best Practices, LLC also leveraged its propriety Field Medical Excellence database to provide additional benchmarks for maximal alignment with varied portfolio considerations.

The final study draws on 448 survey responses, representing a benchmark class of over 100 biopharma manufacturers.

Industries Profiled:
Health Care; Pharmaceutical; Diagnostic; Biopharmaceutical; Manufacturing; Biotech; Consumer Products; Medical Device; Chemical; Clinical Research; Laboratories


Companies Profiled:
Abbott; AbbVie; Alexion Pharmaceuticals; Alkermes; Astellas; AstraZeneca; Bayer; BioMarin; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Chiesi; Clovis Oncology; CSL Behring; Curis; Daiichi Sankyo; Dermavant Sciences; Dompé; Eisai; Eurofarma; Exact Sciences; Galapagos; GE Healthcare; Genentech; Gilead Sciences; GlaxoSmithKline ; Grünenthal; Horizon Therapeutics; Ipsen; Janssen; Jazz Pharmaceuticals; Kyowa Kirin; Lundbeck; Merck; Merck KGaA; Merus; Novartis; Novo Nordisk; OM Pharma; Orchard Therapeutics; Pfizer; Radius Health; Inc.; Sanofi; Seres Therapeutics; Servier; Sunovion; Supernus; Takeda Pharmaceuticals; Teva Pharmaceutical Industries Ltd; UCB Pharma; Ultragenyx; Vertex Pharmaceuticals

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.